Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Dermatology and Therapy
|
September 13, 2020
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
Bruno Bregman, Siguroli Teitsson, Isabella Orsini, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 20, 2025
Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of <i>BRAF</i>-mutant advanced melanoma
Kirollos S Hanna, Jennell Palaia, Divya Patel, et al.
Cancer Medicine
|
July 26, 2022
Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
Wolfram Samlowski, Nicholas J Robert, Liwei Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2024
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials
Jeffrey S Weber, Mark R Middleton, Georgia Yates, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2020
Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors
Elisabeth Coart, Stefan Suciu, Pierre Squifflet, et al.
International Journal of Medical Informatics
|
September 13, 2005
Integrating feedback from a clinical data warehouse into practice organisation
Andrew Grant, Andriy Moshyk, Hassan Diab, et al.
BMJ Open
|
January 31, 2025
Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments
Isabella C Glitza Oliva, Jennell Palaia, Leon A Sakkal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 19, 2021
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma
Jeffrey S Weber, Paolo A Ascierto, Mark R Middleton, et al.
MDM Policy & Practice
|
March 31, 2022
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
Victoria Federico Paly, Murat Kurt, Lirong Zhang, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
January 24, 2024
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach
Daniel Serrano, David Cella, Don Husereau, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Dermatology and Therapy
|
September 13, 2020
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
Bruno Bregman, Siguroli Teitsson, Isabella Orsini, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 20, 2025
Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of <i>BRAF</i>-mutant advanced melanoma
Kirollos S Hanna, Jennell Palaia, Divya Patel, et al.
Cancer Medicine
|
July 26, 2022
Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
Wolfram Samlowski, Nicholas J Robert, Liwei Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 8, 2024
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials
Jeffrey S Weber, Mark R Middleton, Georgia Yates, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2020
Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors
Elisabeth Coart, Stefan Suciu, Pierre Squifflet, et al.
International Journal of Medical Informatics
|
September 13, 2005
Integrating feedback from a clinical data warehouse into practice organisation
Andrew Grant, Andriy Moshyk, Hassan Diab, et al.
BMJ Open
|
January 31, 2025
Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments
Isabella C Glitza Oliva, Jennell Palaia, Leon A Sakkal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 19, 2021
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma
Jeffrey S Weber, Paolo A Ascierto, Mark R Middleton, et al.
MDM Policy & Practice
|
March 31, 2022
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
Victoria Federico Paly, Murat Kurt, Lirong Zhang, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
January 24, 2024
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach
Daniel Serrano, David Cella, Don Husereau, et al.
Page
of 3